In such deals, a drug maker agrees to pay a potential rival to delay selling a generic version. The decision may result in lower drug costs, advocates say.
WASHINGTON — A brand-name drug maker can be sued for violating antitrust laws if it agrees to pay a potential competitor to delay selling a generic version, the Supreme Court ruled.
via L.A. Times - Health http://feeds.latimes.com/~r/latimes/features/health/~3/OHc94b__plM/la-fi-court-generic-drugs-20130618,0,7238910.story
WASHINGTON — A brand-name drug maker can be sued for violating antitrust laws if it agrees to pay a potential competitor to delay selling a generic version, the Supreme Court ruled.
via L.A. Times - Health http://feeds.latimes.com/~r/latimes/features/health/~3/OHc94b__plM/la-fi-court-generic-drugs-20130618,0,7238910.story
No comments:
Post a Comment